Sarepta Therapeutics (SRPT) Stock Forecast, Price Target & Predictions
SRPT Stock Forecast
Sarepta Therapeutics stock forecast is as follows: an average price target of $169.93 (represents a 36.33% upside from SRPT’s last price of $124.65) and a rating consensus of 'Buy', based on 20 wall street analysts offering a 1-year stock forecast.
SRPT Price Target
The average price target for Sarepta Therapeutics (SRPT) is $169.93 based on 1-year price targets from 20 Wall Street analysts in the past 3 months, with a price target range of $203.00 to $94.00. This represents a potential 36.33% upside from SRPT's last price of $124.65.
SRPT Analyst Ratings
According to 20 Wall Street analysts, Sarepta Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for SRPT stock is 0 'Strong Buy' (0.00%), 14 'Buy' (70.00%), 5 'Hold' (25.00%), 1 'Sell' (5.00%), and 0 'Strong Sell' (0.00%).
Sarepta Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | Gavin Clark-Gartner | Evercore ISI | $179.00 | $136.40 | 31.23% | 43.60% |
| Aug 08, 2024 | Biren Amin | Piper Sandler | $200.00 | $140.06 | 42.80% | 60.45% |
| Aug 08, 2024 | Gena Wang | Barclays | $203.00 | $140.06 | 44.94% | 62.86% |
| Aug 08, 2024 | Brian Abrahams | RBC Capital | $181.00 | $140.06 | 29.23% | 45.21% |
| Jul 29, 2024 | Brian Abrahams | RBC Capital | $182.00 | $147.88 | 23.07% | 46.01% |
| Jun 27, 2024 | Kostas Biliouris | BMO Capital | $200.00 | $154.79 | 29.21% | 60.45% |
| Jun 26, 2024 | Biren Amin | Piper Sandler | $205.00 | $156.91 | 30.65% | 64.46% |
| Jun 24, 2024 | Gavin Clark-Gartner | Evercore ISI | $185.00 | $160.72 | 15.11% | 48.42% |
| Jun 24, 2024 | Uy Ear | Mizuho Securities | $200.00 | $165.13 | 21.12% | 60.45% |
| Jun 21, 2024 | Brian Skorney | Robert W. Baird | $200.00 | $171.35 | 16.72% | 60.45% |
The latest Sarepta Therapeutics stock forecast, released on Aug 08, 2024 by Gavin Clark-Gartner from Evercore ISI, set a price target of $179.00, which represents a 31.23% increase from the stock price at the time of the forecast ($136.40), and a 43.60% increase from SRPT last price ($124.65).
Sarepta Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 10 | 20 |
| Avg Price Target | - | $193.50 | $179.05 |
| Last Closing Price | $124.65 | $124.65 | $124.65 |
| Upside/Downside | -100.00% | 55.23% | 43.64% |
In the current month, the average price target of Sarepta Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sarepta Therapeutics's last price of $124.65. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 11, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Sep 06, 2024 | Sandler O'Neill | Sector Perform | Sector Perform | Hold |
| Sep 06, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Aug 08, 2024 | Evercore ISI | - | Outperform | Upgrade |
| Aug 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 08, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 08, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Jul 29, 2024 | Sandler O'Neill | Sector Perform | Sector Perform | Hold |
| Jul 29, 2024 | Sandler O'Neil | Underperform | Underperform | Hold |
| Jul 29, 2024 | RBC Capital | Sector Perform | Outperform | Upgrade |
Sarepta Therapeutics's last stock rating was published by BMO Capital on Sep 11, 2024. The company gave SRPT a "Outperform" rating, the same as its previous rate.
Sarepta Therapeutics Financial Forecast
Sarepta Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $396.78M | $331.82M | $261.24M | $253.50M | $258.43M | $230.27M | - | $210.83M | $201.46M | $189.41M | $164.09M | $146.93M | $145.14M | $143.92M | $137.36M | $113.67M | $100.11M | $99.04M | $94.67M | $87.01M | $84.42M | $78.49M |
| Avg Forecast | $866.26M | $809.76M | $743.79M | $710.33M | $565.99M | $408.02M | $394.38M | $379.52M | $387.18M | $285.33M | $255.99M | $241.96M | $250.40M | $234.52M | $220.81M | $206.43M | $197.97M | $178.89M | $167.07M | $145.81M | $150.38M | $137.76M | $115.66M | $234.11M | $98.80M | $98.48M | $91.05M | $86.60M | $78.74M | $55.28M |
| High Forecast | $970.54M | $907.24M | $833.33M | $795.84M | $634.13M | $427.37M | $441.86M | $425.21M | $393.32M | $319.68M | $286.81M | $271.08M | $280.54M | $262.75M | $220.81M | $230.82M | $221.36M | $200.03M | $186.82M | $163.03M | $168.15M | $154.04M | $129.33M | $261.78M | $110.48M | $110.12M | $101.81M | $96.84M | $94.49M | $66.34M |
| Low Forecast | $811.19M | $758.28M | $696.50M | $665.17M | $530.01M | $397.19M | $369.31M | $355.39M | $366.05M | $267.19M | $239.72M | $226.57M | $234.48M | $219.61M | $220.81M | $156.34M | $149.93M | $135.48M | $126.53M | $110.42M | $113.89M | $104.33M | $87.60M | $177.30M | $74.83M | $74.58M | $68.96M | $65.59M | $62.99M | $44.23M |
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 6 | 13 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | 1.02% | 1.16% | 1.02% | 1.05% | 1.03% | 0.98% | - | 1.02% | 1.02% | 1.06% | 0.98% | 1.01% | 0.97% | 1.04% | 1.19% | 0.49% | 1.01% | 1.01% | 1.04% | 1.00% | 1.07% | 1.42% |
Sarepta Therapeutics's average Quarter revenue forecast for Mar 24 based on 6 analysts is $379.52M, with a low forecast of $355.39M, and a high forecast of $425.21M. SRPT's average Quarter revenue forecast represents a -4.35% decrease compared to the company's last Quarter revenue of $396.78M (Dec 23).
Sarepta Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 6 | 13 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | $-28.46M | $-20.84M | $-133.52M | $-107.75M | $-81.49M | $-112.24M | - | $-77.63M | $-95.70M | $-21.42M | $-57.48M | $-142.81M | $-162.47M | $-175.90M | $-130.61M | $2.77M | $-218.40M | $-110.31M | $-261.11M | $-62.85M | $-130.90M | $-62.79M |
| Avg Forecast | $-570.01M | $-532.83M | $-489.42M | $-467.40M | $-372.43M | $-268.48M | $-259.51M | $-94.97M | $-254.77M | $-187.75M | $-168.45M | $-101.57M | $-164.76M | $-30.23M | $-145.30M | $-108.63M | $-134.37M | $-32.33M | $-58.04M | $-116.19M | $-98.95M | $-104.10M | $-118.00M | $4.68M | $-143.71M | $-81.71M | $-190.59M | $-86.15M | $-121.47M | $-40.08M |
| High Forecast | $-533.77M | $-498.96M | $-458.31M | $-437.69M | $-348.75M | $-261.36M | $-243.01M | $-75.98M | $-240.87M | $-175.82M | $-157.74M | $-81.26M | $-154.29M | $-24.18M | $-145.30M | $-86.91M | $-107.49M | $-25.87M | $-46.43M | $-92.95M | $-74.94M | $-83.28M | $-94.40M | $5.61M | $-114.97M | $-65.37M | $-152.47M | $-68.92M | $-97.18M | $-32.06M |
| Low Forecast | $-638.63M | $-596.97M | $-548.34M | $-523.67M | $-417.26M | $-281.22M | $-290.75M | $-113.96M | $-258.81M | $-210.36M | $-188.72M | $-121.89M | $-184.60M | $-36.28M | $-145.30M | $-130.36M | $-161.24M | $-38.80M | $-69.65M | $-139.42M | $-110.64M | $-124.92M | $-141.60M | $3.74M | $-172.45M | $-98.05M | $-228.71M | $-103.38M | $-145.76M | $-48.09M |
| Surprise % | - | - | - | - | - | - | - | - | 0.11% | 0.11% | 0.79% | 1.06% | 0.49% | 3.71% | - | 0.71% | 0.71% | 0.66% | 0.99% | 1.23% | 1.64% | 1.69% | 1.11% | 0.59% | 1.52% | 1.35% | 1.37% | 0.73% | 1.08% | 1.57% |
10 analysts predict SRPT's average Quarter EBITDA for Jun 20 to be $-118.00M, with a high of $-94.40M and a low of $-141.60M. This is -4364.40% lower than Sarepta Therapeutics's previous annual EBITDA (Mar 20) of $2.77M.
Sarepta Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 6 | 13 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| Net Income | - | - | - | - | - | - | - | - | $45.66M | $-40.94M | $-23.94M | $-516.75M | $-109.24M | $-257.74M | - | $-105.03M | $-121.98M | $-48.14M | $-81.41M | $-167.25M | $-189.32M | $-196.50M | $-150.82M | $-17.49M | $-235.70M | $-126.33M | $-276.40M | $-76.64M | $-140.90M | $-76.39M |
| Avg Forecast | $303.41M | $275.02M | $267.45M | $207.53M | $126.46M | $4.04M | $-12.25M | $-111.22M | $6.52M | $-115.73M | $-168.12M | $-118.95M | $-139.45M | $-67.96M | $-109.85M | $-127.22M | $-145.01M | $-72.68M | $-82.20M | $-136.07M | $-190.13M | $-116.29M | $-136.25M | $-29.56M | $-155.09M | $-93.57M | $-201.75M | $-105.05M | $-130.75M | $-48.76M |
| High Forecast | $350.89M | $318.06M | $309.31M | $240.01M | $146.24M | $10.77M | $-11.24M | $-88.98M | $223.96M | $-106.16M | $-154.22M | $-95.16M | $-127.92M | $-54.37M | $-109.85M | $-101.78M | $-116.01M | $-58.15M | $-65.76M | $-108.85M | $-130.15M | $-93.03M | $-109.00M | $-23.65M | $-124.08M | $-74.86M | $-161.40M | $-84.04M | $-104.60M | $-39.01M |
| Low Forecast | $278.33M | $252.29M | $245.35M | $190.38M | $116.00M | $-5.39M | $-14.17M | $-133.47M | $-86.97M | $-133.84M | $-194.43M | $-142.74M | $-161.27M | $-81.55M | $-109.85M | $-152.67M | $-174.02M | $-87.22M | $-98.63M | $-163.28M | $-219.33M | $-139.55M | $-163.50M | $-35.47M | $-186.11M | $-112.29M | $-242.10M | $-126.06M | $-156.90M | $-58.51M |
| Surprise % | - | - | - | - | - | - | - | - | 7.00% | 0.35% | 0.14% | 4.34% | 0.78% | 3.79% | - | 0.83% | 0.84% | 0.66% | 0.99% | 1.23% | 1.00% | 1.69% | 1.11% | 0.59% | 1.52% | 1.35% | 1.37% | 0.73% | 1.08% | 1.57% |
Sarepta Therapeutics's average Quarter net income forecast for Mar 24 is $-111.22M, with a range of $-133.47M to $-88.98M. SRPT's average Quarter net income forecast represents a -343.61% decrease compared to the company's last Quarter net income of $45.66M (Dec 23).
Sarepta Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 6 | 13 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| SG&A | - | - | - | - | - | - | - | - | $131.70M | $120.89M | $118.56M | $110.71M | $120.48M | $104.79M | - | $71.84M | $78.06M | $61.13M | $72.35M | $71.13M | $86.21M | $75.54M | $73.85M | $82.93M | $81.62M | $75.64M | $67.61M | $60.78M | $64.44M | $53.26M |
| Avg Forecast | $452.28M | $422.78M | $388.34M | $370.86M | $295.51M | $213.03M | $205.91M | $47.30M | $202.15M | $148.97M | $133.66M | $50.59M | $130.73M | $86.28M | $115.29M | $54.11M | $50.22M | $92.28M | $73.05M | $57.87M | $78.51M | $44.70M | $66.72M | $140.15M | $53.71M | $56.03M | $49.35M | $83.31M | $59.80M | $33.99M |
| High Forecast | $506.73M | $473.67M | $435.09M | $415.51M | $331.08M | $223.13M | $230.70M | $56.76M | $205.36M | $166.91M | $149.75M | $60.71M | $146.47M | $103.54M | $115.29M | $64.93M | $60.26M | $110.74M | $87.66M | $69.44M | $87.79M | $53.65M | $80.06M | $168.18M | $64.45M | $67.24M | $59.22M | $99.97M | $71.75M | $40.79M |
| Low Forecast | $423.53M | $395.90M | $363.65M | $347.29M | $276.72M | $207.38M | $192.82M | $37.84M | $191.12M | $139.50M | $125.16M | $40.47M | $122.42M | $69.03M | $115.29M | $43.29M | $40.17M | $73.83M | $58.44M | $46.30M | $59.46M | $35.76M | $53.38M | $112.12M | $42.97M | $44.83M | $39.48M | $66.65M | $47.84M | $27.20M |
| Surprise % | - | - | - | - | - | - | - | - | 0.65% | 0.81% | 0.89% | 2.19% | 0.92% | 1.21% | - | 1.33% | 1.55% | 0.66% | 0.99% | 1.23% | 1.10% | 1.69% | 1.11% | 0.59% | 1.52% | 1.35% | 1.37% | 0.73% | 1.08% | 1.57% |
Sarepta Therapeutics's average Quarter SG&A projection for Mar 24 is $47.30M, based on 6 Wall Street analysts, with a range of $37.84M to $56.76M. The forecast indicates a -64.08% fall compared to SRPT last annual SG&A of $131.70M (Dec 23).
Sarepta Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 6 | 13 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| EPS | - | - | - | - | - | - | - | - | $0.79 | $-0.46 | $-0.27 | $-5.86 | $-1.34 | $-2.94 | - | $-1.20 | $-1.53 | $-0.60 | $-1.02 | $-2.10 | $-2.41 | $-2.50 | $-1.93 | $-0.23 | $-3.08 | $-1.70 | $-3.74 | $-1.07 | $-2.05 | $-1.15 |
| Avg Forecast | $3.21 | $2.91 | $2.83 | $2.19 | $1.34 | $0.04 | $-0.13 | $0.01 | $0.07 | $-1.22 | $-1.78 | $-1.30 | $-1.47 | $-1.22 | $-1.11 | $-1.31 | $-1.26 | $-1.79 | $-1.30 | $-1.83 | $-1.80 | $-1.71 | $-1.72 | $-1.92 | $-1.81 | $-1.35 | $-1.07 | $-1.64 | $-0.95 | $-0.52 |
| High Forecast | $3.71 | $3.36 | $3.27 | $2.54 | $1.55 | $0.11 | $-0.12 | $0.01 | $2.37 | $-1.12 | $-1.63 | $-1.19 | $-1.35 | $-1.12 | $-1.11 | $-0.90 | $-0.86 | $-1.22 | $-0.89 | $-1.25 | $-1.23 | $-1.17 | $-1.18 | $-1.31 | $-1.24 | $-0.93 | $-0.73 | $-1.13 | $-0.76 | $-0.41 |
| Low Forecast | $2.94 | $2.67 | $2.59 | $2.01 | $1.23 | $-0.06 | $-0.15 | $0.01 | $-0.92 | $-1.41 | $-2.05 | $-1.50 | $-1.70 | $-1.42 | $-1.11 | $-1.51 | $-1.45 | $-2.06 | $-1.50 | $-2.11 | $-2.08 | $-1.97 | $-1.99 | $-2.21 | $-2.08 | $-1.56 | $-1.23 | $-1.90 | $-1.14 | $-0.62 |
| Surprise % | - | - | - | - | - | - | - | - | 11.46% | 0.38% | 0.15% | 4.51% | 0.91% | 2.40% | - | 0.91% | 1.22% | 0.34% | 0.79% | 1.15% | 1.34% | 1.46% | 1.12% | 0.12% | 1.71% | 1.26% | 3.51% | 0.65% | 2.16% | 2.21% |
According to 6 Wall Street analysts, Sarepta Therapeutics's projected average Quarter EPS for Mar 24 is $0.01, with a low estimate of $0.01 and a high estimate of $0.01. This represents a -98.37% decrease compared to SRPT previous annual EPS of $0.79 (Dec 23).
Sarepta Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| IOVA | Iovance Biotherapeutics | $10.34 | $21.57 | 108.61% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| VKTX | Viking Therapeutics | $66.73 | $100.50 | 50.61% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| SRPT | Sarepta Therapeutics | $124.65 | $169.93 | 36.33% | Buy |
| MDGL | Madrigal Pharmaceuticals | $241.80 | $315.75 | 30.58% | Buy |
| PTCT | PTC Therapeutics | $33.99 | $44.33 | 30.42% | Hold |
| KRYS | Krystal Biotech | $201.58 | $191.00 | -5.25% | Buy |
SRPT Forecast FAQ
Is Sarepta Therapeutics a good buy?
Yes, according to 20 Wall Street analysts, Sarepta Therapeutics (SRPT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 70.00% of SRPT's total ratings.
What is SRPT's price target?
Sarepta Therapeutics (SRPT) average price target is $169.93 with a range of $94 to $203, implying a 36.33% from its last price of $124.65. The data is based on 20 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Sarepta Therapeutics stock go up soon?
According to Wall Street analysts' prediction for SRPT stock, the company can go up by 36.33% (from the last price of $124.65 to the average price target of $169.93), up by 62.86% based on the highest stock price target, and down by -24.59% based on the lowest stock price target.
Can Sarepta Therapeutics stock reach $200?
SRPT's highest twelve months analyst stock price target of $203 supports the claim that Sarepta Therapeutics can reach $200 in the near future.
What are Sarepta Therapeutics's analysts' financial forecasts?
Sarepta Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $1.75B (high $1.93B, low $1.65B), average EBITDA is $-995M (high $-929M, low $-1.103B), average net income is $7.02M (high $56.8M, low $-37.017M), average SG&A $761.75M (high $841.67M, low $714.76M), and average EPS is $1.26 (high $1.56, low $1.03). SRPT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.13B (high $3.51B, low $2.93B), average EBITDA is $-2.06B (high $-1.929B, low $-2.308B), average net income is $1.05B (high $1.22B, low $966.35M), average SG&A $1.63B (high $1.83B, low $1.53B), and average EPS is $11.13 (high $12.88, low $10.21).
Did the SRPT's actual financial results beat the analysts' financial forecasts?
Based on Sarepta Therapeutics's last annual report (Dec 2023), the company's revenue was $1.24B, beating the average analysts forecast of $1.17B by 6.23%. Apple's EBITDA was $-268M, missing the average prediction of $-713M by -62.41%. The company's net income was $-536M, beating the average estimation of $-396M by 35.25%. Apple's SG&A was $481.87M, missing the average forecast of $535.37M by -9.99%. Lastly, the company's EPS was $-5.8, beating the average prediction of $-4.229 by 37.14%. In terms of the last quarterly report (Dec 2023), Sarepta Therapeutics's revenue was $396.78M, beating the average analysts' forecast of $387.18M by 2.48%. The company's EBITDA was $-28.46M, missing the average prediction of $-255M by -88.83%. Sarepta Therapeutics's net income was $45.66M, beating the average estimation of $6.52M by 599.91%. The company's SG&A was $131.7M, missing the average forecast of $202.15M by -34.85%. Lastly, the company's EPS was $0.79, beating the average prediction of $0.0689 by 1045.92%